

Supplementary table 5. USF1 SNPs and haplotypes and their association with SP type and NFT prevalence (APOE4 carriership as a covariate) in over 65 year old.

	rs10908821				rs2073658				rs2774276				rs2516839				rs1556259				rs2774279			
	Aff. (%) CC*/G+	OR	CI	p	Aff. (%) CC*/T+	OR	CI	p	Aff. (%) CC*/G+	OR	CI	p	Aff. (%) TT*/C+	OR	CI	p	Aff. (%) AA*/G+	OR	CI	p	Aff. (%) CC*/T+	OR	CI	p
SP	89(44.1)/43(61.4)	2.01	1.14-3.55	0.016	51(48.6)/80(48.2)	0.99	0.61-1.65	NS	72(47.7)/60(49.2)	1.08	0.66-1.77	NS	49(45.0)/83(50.9)	1.23	0.75-2.03	NS	101(47.6)/29(50.0)	1.08	0.59-1.95	NS	77(51.0)/55(45.5)	0.80	0.49-1.31	NS
Non neuritic	20(10.1)/11(16.4)	2.05	0.88-4.75	NS	10(9.9)/21(12.9)	1.41	0.62-3.23	NS	17(11.4)/14(12.0)	1.01	0.46-2.20	NS	11(10.2)/20(12.7)	1.29	0.57-2.90	NS	23(11.2)/8(14.0)	1.37	0.55-3.38	NS	21(14.2)/10(8.5)	0.54	0.24-1.22	NS
Neuritic	64(32.3)/26(38.8)	1.52	0.82-2.82	NS	34(33.7)/55(33.7)	1.08	0.62-1.88	NS	52(34.9)/38(32.5)	0.91	0.53-1.56	NS	36(33.3)/54(34.4)	1.07	0.62-1.85	NS	68(33.0)/20(35.1)	1.16	0.60-2.24	NS	51(34.5)/39(33.3)	0.84	0.49-1.45	NS
Diffuse	6(3.0)/3(4.5)	1.91	0.45-8.08	NS	3(3.0)/6(3.7)	1.31	0.31-5.45	NS	5(3.4)/4(3.4)	0.99	0.25-3.82	NS	6(3.8)/8(7.4)	1.48	0.36-6.17	NS	6(2.9)/3(5.3)	1.99	0.47-8.43	NS	5(3.4)/4(3.4)	0.89	0.23-3.46	NS
Primitive	14(7.1)/8(11.9)	2.11	0.81-5.52	NS	7(6.9)/15(9.2)	1.46	0.56-3.82	NS	12(8.1)/10(8.5)	1.01	0.41-2.51	NS	14(8.9)/27(25.0)	1.22	0.48-3.11	NS	17(8.3)/5(8.8)	1.14	0.39-3.38	NS	16(10.8)/6(5.1)	0.42	0.16-1.15	NS
Classic	47(23.7)/18(26.9)	1.44	0.72-2.87	NS	23(22.8)/42(25.8)	1.21	0.65-2.25	NS	39(26.2)/27(23.1)	0.86	0.48-1.57	NS	27(25.0)/38(24.2)	1.02	0.55-1.87	NS	49(23.8)/16(28.1)	1.30	0.64-2.63	NS	37(25.0)/28(23.9)	0.82	0.45-1.50	NS
Burnt out	17(8.6)/8(11.9)	1.71	0.67-4.40	NS	11(10.9)/13(8.0)	0.81	0.34-1.95	NS	13(8.7)/11(9.4)	1.03	0.43-2.46	NS	9(8.3)/16(10.2)	1.21	0.50-2.95	NS	19(9.2)/4(7.0)	0.81	0.25-2.60	NS	14(9.5)/11(9.4)	0.89	0.38-2.11	NS
Cerad ≤1.5%	38(18.8)/18(25.7)	1.95	0.96-3.96	NS	22(21.0)/34(20.5)	0.99	0.52-1.90	NS	33(21.9)/23(18.9)	0.89	0.47-1.69	NS	22(20.2)/34(20.9)	1.11	0.58-2.10	NS	41(19.3)/14(24.1)	1.27	0.60-2.67	NS	31(20.5)/25(20.7)	0.92	0.49-1.73	NS
Cerad >1.5%	51(25.2)/25(35.7)	2.06	1.07-3.93	0.030	29(27.6)/46(27.7)	1.00	0.56-1.80	NS	39(25.8)/37(30.3)	1.25	0.71-2.21	NS	27(24.8)/49(30.1)	1.34	0.74-2.43	NS	60(28.3)/15(25.9)	0.94	0.46-1.92	NS	46(30.5)/30(24.8)	0.72	0.40-1.29	NS
NFT	106(62.0)/39(66.1)	1.15	0.62-2.15	NS	58(64.4)/87(62.6)	0.96	0.55-1.66	NS	81(64.8)/66(62.3)	0.88	0.51-1.51	NS	57(62.6)/88(63.3)	0.98	0.56-1.70	NS	112(62.6)/32(65.3)	1.10	0.56-2.13	NS	80(61.1)/65(65.7)	1.26	0.73-2.18	NS
	Haplotype 2 (CCCTAT)				Haplotype 3 (CCCCGC)				Haplotype 4 (CCGCAC)				Haplotype 5 (CTCTAC)				Haplotype 7 (GCGCAC)							
	Aff. (%) H2*/H2+	OR	CI	p	Aff. (%) H3*/H3+	OR	CI	p	Aff. (%) H4*/H4+	OR	CI	p	Aff. (%) H5*/H5+	OR	CI	p	Aff. (%) H7*/H7+	OR	CI	p				
SP	85(51.5)/55(45.5)	0.80	0.49-1.29	NS	109(48.2)/31(51.7)	1.14	0.64-2.04	NS	116(52.5)/24(36.9)	0.56	0.32-1.01	0.053	53(48.6)/87(49.2)	1.01	0.62-1.65	NS	96(44.9)/44(61.1)	1.97	1.13-3.43	0.017				
Non neuritic	25(14.9)/10(8.5)	0.51	0.23-1.14	NS	27(11.9)/8(13.6)	1.26	0.52-3.08	NS	30(13.5)/5(7.9)	0.46	0.17-1.26	NS	10(9.5)/25(13.9)	1.59	0.71-3.57	NS	24(11.1)/11(15.9)	1.80	0.79-4.08	NS				
Neuritic	57(33.9)/39(33.3)	0.87	0.51-1.48	NS	74(32.7)/22(37.3)	1.30	0.69-2.46	NS	80(36.0)/16(25.4)	0.56	0.29-1.09	NS	36(34.3)/60(33.3)	1.03	0.60-1.76	NS	69(31.9)/27(39.1)	1.58	0.86-2.89	NS				
Diffuse	7(4.2)/4(3.4)	0.73	0.20-2.58	NS	8(3.5)/3(5.1)	1.61	0.40-6.45	NS	10(4.5)/1(1.6)	0.27	0.03-2.16	NS	3(2.9)/8(4.4)	1.67	0.42-6.53	NS	8(3.7)/3(4.3)	1.48	0.37-5.93	NS				
Primitive	18(10.7)/6(5.1)	0.43	0.16-1.15	NS	19(8.4)/5(8.5)	1.12	0.38-3.27	NS	20(9.0)/4(6.3)	0.56	0.18-1.74	NS	7(6.7)/17(9.4)	1.55	0.60-4.00	NS	16(7.4)/8(11.6)	1.96	0.76-5.03	NS				
Classic	43(25.6)/28(23.9)	0.82	0.46-1.48	NS	55(24.3)/16(27.1)	1.28	0.64-2.58	NS	61(27.5)/10(15.9)	0.47	0.22-1.00	0.051	24(22.9)/47(26.1)	1.19	0.65-2.17	NS	52(24.1)/19(27.5)	1.49	0.77-2.90	NS				
Burnt out	14(8.3)/11(9.4)	1.01	0.43-2.39	NS	19(8.4)/6(10.2)	1.34	0.48-3.69	NS	19(8.6)/6(9.5)	0.88	0.33-2.39	NS	12(11.4)/13(7.2)	0.69	0.29-1.64	NS	17(7.9)/8(11.6)	1.84	0.72-4.70	NS				
Cerad ≤1.5%	35(21.7)/25(20.7)	0.85	0.46-1.58	NS	45(20.3)/15(25.0)	1.28	0.62-2.63	NS	51(23.5)/9(13.8)	0.46	0.21-1.03	0.057	22(20.2)/38(22.0)	1.12	0.60-2.11	NS	42(20.0)/18(25.0)	1.76	0.88-3.53	NS				
Cerad >1.5%	48(29.8)/30(24.8)	0.74	0.42-1.31	NS	62(27.9)/16(26.7)	1.02	0.51-2.05	NS	63(29.0)/15(23.1)	0.64	0.33-1.27	NS	31(28.4)/47(27.2)	0.95	0.53-1.69	NS	52(24.8)/26(36.1)	2.13	1.12-4.04	0.020				
NFT	90(59.6)/65(65.7)	1.36	0.80-2.31	NS	122(61.3)/33(64.7)	1.14	0.60-2.17	NS	126(66.0)/29(49.2)	0.50	0.28-0.91	0.024	60(63.8)/95(60.9)	0.89	0.53-1.52	NS	114(60.3)/41(67.2)	1.32	0.72-2.44	NS				

*denotes the most common haplotype/homozygous genotype acting as the reference group in the analyses. Aff.(%) refers to number of individuals affected with SP/NFT.

USF1 – upstream transcription factor 1 gene, SNPs – single nucleotide polymorphisms, SP – senile plaques, NFT – neurofibrillary tangles, APOE4 – Apolipoprotein E ε4, OR – odds ratio, CI – confidence interval, p – p-value, NS – non significant p-value